GC3 Strategy is the operational partner to MidAtlantic COVID Response, a public private partnership platform helping the Northeast Corridor get back to work — safely, inclusively and resiliently — from Washington DC to Boston MA. The MidAtlantic COVID Response platform synergizes philanthropy-led solutions for vulnerable workers with private sector-led technology solutions for mid-market companies and local governments and hospital systems. The meshing fills gaps and produces efficacy solutions greater than the sum of the component parts for this hard-hit, heavily traveled regional corridor. GC3 Strategy’s role on the MidAtlantic COVID Response platform is to manage a suite of best-of-breed technology solutions — including diagnostic testing tools, contact tracing tools, reliable and high-quality PPE sourcing, and specialty tools — which evolves as the pandemic and market needs evolve. GC3 Strategy provides this suite to platform partners at below-market pricing and with local accountability for pricing, quality and availability.
For further detail, see our Executive Summary
Vice President for Communications & Diversity, Equity & Inclusion
Love Malone is the Founder and CEO of The Gradient Group. Prior to starting the Gradient Group, Love was an award-winning advertising, marketing, and sales executive with experiences at companies including Oglivy and Mather, BBDO Worldwide, GlaxoSmithKline and Merck. She worked with global companies in creating advertising content and brand sponsorships for companies including Merck, Pinnacle Foods, Janssen, Universal Pictures, BlackRock, iShares and Genentech.
Chief Operating Officer
Mr. Wayne Stewart Morrison has 40 years of experience in finance, leadership, entrepreneurship, capital markets, asset management and sports and leisure real estate development. He is currently the CEO of SixRock Group, LLC, a sports and leisure development company with projects in Tianjin and Chengde, Peoples Republic of China. Mr. Morrison was a Director at Bucephale Global Asset
Management in Geneva Switzerland, responsible for the turnaround of one of the oldest fund of funds in Europe after the death of the founder. Mr. Morrison was a founder of Glenveigh Holding Company, LLC, organized to develop high-end residential and golf communities in the United States. Prior to Glenveigh, Mr. Morrison worked in the capital markets as a director of derivative trading
(equities, indexes and currencies) for twenty-three years on the Philadelphia and American Stock Exchanges, serving on a number of governance committees on each exchange.
Richard Serbin has six decades of experience in healthcare, initially as a registered pharmacist, then as an attorney and patent attorney for Schering- Plough. In the late 1970s, Mr. Serbin was the Chief FDA counsel at Revlon and Johnson & Johnson. In the 1980s, Mr. Serbin started several companies including Medication Services, Inc. and Advanced Therapeutics Communications where he was President and Chief Executive Officer. In the 1990s, Mr. Serbin was a C-level executive at Lifetime Corporation, Oxford Delta Research (sold to Sandler Communications) and a co-founder of Bio-Imaging Technologies, Inc. (IPO). Since 2000, Mr. Serbin was President at Bradley Pharmaceuticals, Optigenex Inc. and is currently the founder and CEO of Seaweed Bio-Technology, Inc.
“The combination of national and subnational measures and an ability to work together, is fundamental for an effective response to this pandemic crisis.”— OECD